You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia

    SBC: MICROFLUIDIC INNOVATIONS, LLC            Topic: 102

    DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Hit Detection Systems

    SBC: FREENT TECHNOLOGIES, INC.            Topic: MDA13015

    FreEnt Technologies, Inc. (FreEnt) and Johns Hopkins Universitys Applied Physics Laboratory (APL) are proposing a multiple-hit detection sensor called the Optical Lethality Measurement System (OLMS). This system is based on the Planar Optical Penetration Sensor (POPS) technology (originally developed and patented by APL) and prior art associated with the Blast Initiation Detector (BID). The BID is ...

    STTR Phase II 2017 Department of DefenseMissile Defense Agency
  3. A new generation of targeted therapeutics for the treatment of cancer

    SBC: NERX BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. A Novel, Microscale, Distributable Sensor Technology for Ionizing Radiation

    SBC: CFD RESEARCH CORPORATION            Topic: DTRA14B004

    Terrorist use of radioactive nuclear materials via nuclear and/or radiological dispersion devices (dirty bombs) is a serious threat. Therefore, it is critical to detect the proliferation of nuclear material. Critical challenges facing this objective include: (a) high sensitivity detection of signature emissions (e.g., gamma rays) from common radioactive isotopes behind shielding, and (b) cost-effe ...

    STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency
  5. A Novel Probiotic Platform to Treat Necrotizing Enterocolitis

    SBC: MONON BIOVENTURES LLC            Topic: 300

    PROJECT SUMMARY Probiotics hold enormous potential for promoting human health and treating disease One major hurdle to many probiotic products is their lack of persistence in the gut Monon Bioventures MBV and their research partners at the Research Institute at Nationwide Childrenandapos s Hospital RINCH are developing a novel enhanced tunable technology called ProNextTM that allows for a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Base Metal Electrode Capacitor Test Methods

    SBC: FUNDO SCIENCE CORPORATION            Topic: MDA14T003

    Miniaturized base metal electrodes (BME) multilayer ceramic capacitors (MLCC) are of great interest for future missile applications as designers are striving to achieve smaller, lighter, cheaper, faster and better electronic assemblies without sacrificing long-term performance. Unfortunately, screening, reliability and qualifications criteria are either not available or not standardized. In the ...

    STTR Phase I 2015 Department of DefenseMissile Defense Agency
  7. Commercialization of a Novel Therapeutic for Alzheimer's Disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Novel Membrane Protein Solubilization/Stabilization Screen

    SBC: SOLUBLE THERAPEUTICS, INC            Topic: 100

    DESCRIPTION provided by applicant The increasing output of new integral membrane protein IMP structures is partially due to the availability of an increasing number of chemical variables such as detergents detergent like molecules lipids and solubilizing stabilizing additives It is clear that specific combinations and concentrations of these different variables are often necessary to impr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Development of CaSR nutrient therapy for childhood diarrhea

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Project Abstract Acute infectious diarrhea is a worldwide problem especially among infants young children and immune compromised patients Sadly million children die each year not because of the infections causing diarrhea but due to the associated dehydration The pro absorptive Oral Rehydration Solution ORS is the only recommended oral therapy for children with acute diarrhea yet it ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography

    SBC: Vibronix, Inc.            Topic: 102

    DESCRIPTION provided by applicant Prostate cancer PCa is the No killer among male cancer patients The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues This conventional diagnostic procedure is invasive missing cases of cancer due to small sampling volume Moreover it leads to an overtreatment of patients du ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government